Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

Схожие документы

• Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
  по: Harrison, C N, et al.
  Опубликовано: (2016)
• The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis
  по: McMullin, Mary Frances, et al.
  Опубликовано: (2015)
• Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies
  по: Mesa, Ruben A., et al.
  Опубликовано: (2014)
• A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
  по: Vannucchi, Alessandro M., et al.
  Опубликовано: (2015)
• Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
  по: Verstovsek, Srdan, et al.
  Опубликовано: (2017)